Given the implication of METTL3 in the development and progression of numerous cancer types, there has been considerable interest in small molecule METTL3 inhibitors, that have recently demonstrated preclinical proof of concept evidence for the treatment of leukaemia (Yankova et al., 2021). This evidence concerns the gene METTL3 and cancer.